Overview

BIBW 2992 as add-on to Gem/Cis in Advanced Biliary Tract Cancer

Status:
Terminated
Trial end date:
2016-04-01
Target enrollment:
Participant gender:
Summary
An open-label, uncontrolled, multicenter phase I/Ib trial to investigate safety and efficacy of BIBW 2992 added to the standard therapy of Gemcitabine/Cisplatin in chemo-naïve patients with advanced and/or metastatic adenocarcinoma of the biliary tract
Phase:
Phase 1
Details
Lead Sponsor:
Johannes Gutenberg University Mainz
Treatments:
Afatinib
Cisplatin
Gemcitabine